In today’s briefing:
- July TOPIX FFW Rebal – Bigger Than Expected
- Genda IPO – Dreams of Reviving the Domestic Arcade Industry with a Roadmap of Doing so as Well
- Takeda: The Impact of Voluntary Withdrawal of Dengue Vaccine Application in the US Seems Minimal
July TOPIX FFW Rebal – Bigger Than Expected
- Last Friday, the FFW changes for the TOPIX July Free Float Weight Review were announced. There have also been other recent announcements creating flows on 30 July.
- Some of these other recent announcements represent a possible change in ad hoc methodology.
- Total Flow for 30 July is ~$3.3bn a side driven by selling flows (3/4 of the buy flows are reverse funding). $2.1bn of selling is > 3 days ADV.
Genda IPO – Dreams of Reviving the Domestic Arcade Industry with a Roadmap of Doing so as Well
- Genda Inc (9166 JP) is looking to raise around US$100m in its Japan IPO.
- Genda develops and operates amusement facilities in Japan, primarily operating under its Genda GiGO Entertainment subsidiary.
- As of Apr 23, the firm operated 250 amusement facilities domestically and four facilities in Taiwan.
Takeda: The Impact of Voluntary Withdrawal of Dengue Vaccine Application in the US Seems Minimal
- Takeda Pharmaceutical (4502 JP) announced yesterday that the company has voluntarily withdrawn the US Biologic License Application for dengue vaccine candidate (QDENGA) citing issues over data collection.
- As per Fierce Pharma, the decision to withdraw was due to additional data requested by the FDA which were not captured by Takeda’s Phase 3 TIDES trial.
- Takeda’s share price dropped more than 2.0% during today’s trade, however, we would not be too concerned as efficacy and safety profiles of the trial has already been established.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
